166 related articles for article (PubMed ID: 11062273)
1. Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo.
Diener HC; Cortens M; Ford G; Grotta J; Hacke W; Kaste M; Koudstaal PJ; Wessel T
Stroke; 2000 Nov; 31(11):2543-51. PubMed ID: 11062273
[TBL] [Abstract][Full Text] [Related]
2. Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Lubeluzole International Study Group.
Diener HC; Hacke W; Hennerici M; Rådberg J; Hantson L; De Keyser J
Stroke; 1996 Jan; 27(1):76-81. PubMed ID: 8553408
[TBL] [Abstract][Full Text] [Related]
3. Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group.
Grotta J
Stroke; 1997 Dec; 28(12):2338-46. PubMed ID: 9412611
[TBL] [Abstract][Full Text] [Related]
4. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group.
Diener HC
Cerebrovasc Dis; 1998; 8(3):172-81. PubMed ID: 9619701
[TBL] [Abstract][Full Text] [Related]
5. Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole.
Grotta J;
Cerebrovasc Dis; 2001; 12(3):258-63. PubMed ID: 11641593
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety of lubeluzole (Prosynap(R)) in patients with ischemic stroke.
Hacke W; Lees KR; Timmerhuis T; Haan J; Hantson L; Hennerici M; Diener HC
Cerebrovasc Dis; 1998; 8(5):247-54. PubMed ID: 9712921
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of the neuroprotective drug lubeluzole in patients with ischemic stroke.
De Keyser J; Van de Velde V; Schellens RL; Hantson L; Tritsmans L; Gheuens J; Van Peer A; Woestenborghs R; Franke CL; van Gorp J
Clin Ther; 1997; 19(6):1340-51. PubMed ID: 9444444
[TBL] [Abstract][Full Text] [Related]
8. Lubeluzole for acute ischaemic stroke.
Gandolfo C; Sandercock P; Conti M
Cochrane Database Syst Rev; 2002; (1):CD001924. PubMed ID: 11869612
[TBL] [Abstract][Full Text] [Related]
9. Determination of the dose proportionality of single intravenous doses (5, 10, and 15 mg) of lubeluzole in healthy volunteers.
Herron J; Lee P; Pesco-Koplowitz L; Gajjar D; Soo YW; Woestenborghs R
Clin Ther; 1998; 20(4):682-90. PubMed ID: 9737828
[TBL] [Abstract][Full Text] [Related]
10. The safety and tolerability of single intravenous doses of lubeluzole (Prosynap) in healthy volunteers.
Hantson L; Tritsmans L; Crabbé R; Gheuens J; Van Rooy P
Int J Clin Pharmacol Ther; 1997 Nov; 35(11):491-5. PubMed ID: 9401829
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT).
Teal P; Davis S; Hacke W; Kaste M; Lyden PD; ; Fierus M;
Stroke; 2009 Nov; 40(11):3518-25. PubMed ID: 19745176
[TBL] [Abstract][Full Text] [Related]
12. Glycine antagonist (GV150526) in acute stroke: a multicentre, double-blind placebo-controlled phase II trial.
Lees KR; Lavelle JF; Cunha L; Diener HC; Sanders EA; Tack P; Wester P;
Cerebrovasc Dis; 2001; 11(1):20-9. PubMed ID: 11173790
[TBL] [Abstract][Full Text] [Related]
13. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.
Clark WM; Albers GW; Madden KP; Hamilton S
Stroke; 2000 Apr; 31(4):811-6. PubMed ID: 10753980
[TBL] [Abstract][Full Text] [Related]
14. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke.
Dyker AG; Lees KR
Stroke; 1999 Sep; 30(9):1796-801. PubMed ID: 10471426
[TBL] [Abstract][Full Text] [Related]
15. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.
Heiss WD; Brainin M; Bornstein NM; Tuomilehto J; Hong Z;
Stroke; 2012 Mar; 43(3):630-6. PubMed ID: 22282884
[TBL] [Abstract][Full Text] [Related]
16. Lubeluzole. JK 8792, R 87926, Prosynap.
Drugs R D; 1999 Jan; 1(1):29-31. PubMed ID: 10565978
[No Abstract] [Full Text] [Related]
17. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
18. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
Hacke W; Albers G; Al-Rawi Y; Bogousslavsky J; Davalos A; Eliasziw M; Fischer M; Furlan A; Kaste M; Lees KR; Soehngen M; Warach S;
Stroke; 2005 Jan; 36(1):66-73. PubMed ID: 15569863
[TBL] [Abstract][Full Text] [Related]
19. NXY-059 for acute ischemic stroke.
Lees KR; Zivin JA; Ashwood T; Davalos A; Davis SM; Diener HC; Grotta J; Lyden P; Shuaib A; Hårdemark HG; Wasiewski WW;
N Engl J Med; 2006 Feb; 354(6):588-600. PubMed ID: 16467546
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of lubeluzole (Prosynap) after single intravenous doses in healthy subjects.
Van de Velde V; Crabbe R; Van Peer A; Woestenborghs R; Van Osselaer N; Hantson L; Heykants J
Int J Clin Pharmacol Ther; 1998 Sep; 36(9):490-3. PubMed ID: 9760010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
